Variability of endogenous deoxyribonuclease activity and its pathophysiological consequences.

Cell-free DNA DAMPs Deoxyribonuclease Mitochondrial DNA Toll-like receptor 9

Journal

Molecular and cellular probes
ISSN: 1096-1194
Titre abrégé: Mol Cell Probes
Pays: England
ID NLM: 8709751

Informations de publication

Date de publication:
10 2022
Historique:
received: 01 06 2022
revised: 01 07 2022
accepted: 01 07 2022
pubmed: 9 7 2022
medline: 9 9 2022
entrez: 8 7 2022
Statut: ppublish

Résumé

Deoxyribonucleases (DNases) are enzymes that cleave DNA. Some DNases are secreted outside of cells where they can cleave extracellular DNA (ecDNA). High concentration of ecDNA is associated with diseases such as sepsis, preeclampsia, and systemic lupus. DNA can be released from dying cells and is immunogenic. DNases cleave ecDNA and might prevent activation of the immune system. Low DNase activity could be disadvantageous in diseases where high amounts of ecDNA are released from dying cells. The relationship between DNase activity and ecDNA remains unknown. The lack of standard values in DNase activity makes the studies difficult to compare. This review focuses on summarizing methods for DNase activity measurements, the possible implication of decreased DNase activity in diseases, and the impact on diseases associated with a high concentration of ecDNA.

Identifiants

pubmed: 35803442
pii: S0890-8508(22)00055-X
doi: 10.1016/j.mcp.2022.101844
pii:
doi:

Substances chimiques

DNA 9007-49-2
Deoxyribonucleases EC 3.1.-

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101844

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Ľubica Janovičová (Ľ)

Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Jozef Čonka (J)

Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Lucia Lauková (L)

Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia; Center for Biomedical Technology, Department for Health Sciences and Biomedicine, Danube University, 3500, Krems, Austria.

Peter Celec (P)

Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. Electronic address: petercelec@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH